Showing 5781-5790 of 7028 results for "".
- Suneva to Distribute Sinclair Pharma's Silhouette Instalift Sutureshttps://practicaldermatology.com/news/suneva-to-distribute-sinclair-pharmas-silhouette-instalift-sutures/2460372/Suneva Medical, Inc. is the exclusive North American distributor for Sinclair Pharma's Silhouette Instalift sutures "We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio,"
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range incl
- COVID-19 By the Numbers: April 28 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-28-edition/2460365/The CDC now lists nine potential symptoms of COVID-19, though cough and shortness of breath or difficulty breathing remain hallmarks of the disease. CDC says individuals may have COVID-19 if they experience these two symptoms plus at least two of the following: Fever
- Coping with COVID-19: Tips and Tools for Enhancing Virtual Skin Cancer Examshttps://practicaldermatology.com/news/coping-with-covid-19-tips-and-tools-for-enhancing-virtual-skin-cancer-exams-1/2460356/Dermatologists across the country have shut their doors due to the coronavirus pandemic, and little certainty remains about when they will reopen for business as usual. Many are still seeing patients with aggressive squamous cell carcinoma or melanoma, but these patients need to be effectively tr
- San Diego Dermatology Symposium Reschedules to Septemberhttps://practicaldermatology.com/news/san-diego-dermatology-symposium-reschedules-to-september/2460350/San Diego Dermatology Symposium will be held September 11-13, 2020, a shift from its original date. "The safety of our attendees, faculty, and exhibitors is our utmost priority, and we have been closely monitoring guidance from federal, state and local governments, as well as the World Healt
- Navigating the Ins and Outs of Your Insurance Coverage During COVID-19https://practicaldermatology.com/news/navigating-the-ins-and-outs-of-your-insurance-coverage-during-covid-19-1/2460349/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i
- Cynosure Names David Long Global Chief Financial Officerhttps://practicaldermatology.com/news/cynosure-names-david-long-global-chief-financial-officer/2460343/David Long is Cynosure’s new Chief Financial Officer, effective immediately. Until recently, Long served as CFO at Corindus Vascular Robotics, Inc., where he brought the company public and, ultimately, navigated its strategic sale to Siemens.
- CSF Live Virtual Meeting to Assess SBA Loans: Tonighthttps://practicaldermatology.com/news/csf-live-virtual-meeting-to-access-sba-loans-tonight/2460334/As dermatology business owners’ heads are swimming trying to figure out the SBA loan to keep afloat during the COVID crisis, CSF, along with George Hruza, MD, immediate past-president of the AAD, and Greg Morganroth, MD, CEO and Founder of California Skin Institute, will discuss the ins-and
- Wontech Scores FDA Nod for Sandro Dual Laserhttps://practicaldermatology.com/news/wontech-scores-fda-nod-for-sandro-dual-laser/2460333/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant